Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Farooqui, Mohammed Z H, DO, Valdez, Janet, PA, Martyr, Sabrina, MD, Aue, Georg, MD, Saba, Nakhle, MD, Niemann, Carsten U, MD, Herman, Sarah E M, PhD, Tian, Xin, PhD, Marti, Gerald, MD, Soto, Susan, MSN, Hughes, Thomas E, PharmD, Jones, Jade, MD, Lipsky, Andrew, MD, Pittaluga, Stefania, MD, Stetler-Stevenson, Maryalice, MD, Yuan, Constance, MD, Lee, Yuh Shan, MD, Pedersen, Lone B, Geisler, Christian H, Prof, Calvo, Katherine R, MD, Arthur, Diane C, MD, Maric, Irina, MD, Childs, Richard, MD, Young, Neal S, MD, Wiestner, Adrian, Dr
Published in The lancet oncology (01.02.2015)
Published in The lancet oncology (01.02.2015)
Get full text
Journal Article